The effects of knockdown of wild-type survivin, survivin-2B or survivin-Δ3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions

Cancer Gene Therapy

Volumn 14, Issue 12, 2007, Pages 994-1001

  Kappler, M ^a   Rot, S ^a   Taubert, H ^a   Greither, T ^a   Bartel, F ^a   Dellas, K ^a   Hansgen G ^a   Trott, K R ^b   Bache, M ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Hypoxia; Irradiation; siRNA; Soft tissue sarcoma; Survivin; Survivin 3

Indexed keywords

OXYGEN; SURVIVIN; SURVIVIN 2B; SURVIVIN DELTA3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL ASSAY; CELL CULTURE; CELL CYCLE REGULATION; CONTROLLED STUDY; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IRRADIATION; NUCLEOTIDE SEQUENCE; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN VARIANT; RADIOSENSITIZATION; RNA INTERFERENCE; SARCOMA CELL; SOFT TISSUE SARCOMA; WILD TYPE;

CELL CYCLE; CELL HYPOXIA; CELL LINE, TUMOR; GAMMA RAYS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OXYGEN; RADIATION TOLERANCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SARCOMA;

EID: 36148961902     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701090     Document Type: Article

References (49)

1. Altieri DC. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 2006; 5: 478-482.
2. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
3. Kappler M, Kohler T, Kampf C, Diestelkotter P, Wurl P, Schmitz M et al. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer 2001; 95: 360-363.
4. Kappler M, Kotzsch M, Bartel F, Fussel S, Lautenschlager C, Schmidt U et al. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 2003; 9: 1098-1104.
5. Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2000; 2: 235-241.
6. O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000; 156: 393-398.
7. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000; 10: 1319-1328.
8. Reed JC. The Survivin saga goes in vivo. J Clin Invest 2001; 108: 965-969.
9. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003; 22: 2729-2740.
10. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114: 1117-1127.
11. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-3257.
12. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21: 2613-2622.
13. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002; 303: 124-131.
14. Zhu N, Gu L, Findley HW, Li F, Zhou M. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 2004; 23: 7545-7551.
15. Kappler M, Bache M, Bartel F, Kotzsch M, Panian M, Wurl P et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther 2004; 11: 186-193.
16. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1: 461-466.
17. Kallio MJ, Nieminen M, Eriksson JE. Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. FASEB J 2001; 15: 2721-2723.
18. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003; 116: 2987-2998.
19. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 2003; 22: 2934-2947.
20. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003; 9: 931-946.
21. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 2000; 91: 1204-1209.
22. Pennati M, Binda M, Colella G, Folini M, Citti L, Villa R et al. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 2003; 120: 648-654.
23. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003; 55: 1341-1347.
24. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005; 65: 4881-4887.
25. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004; 23: 7494-7506.
26. Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004; 64: 2840-2845.
27. Asanuma K, Kobayashi D, Furuya D, Tsuji N, Yagihashi A, Watanabe N. A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res 2002; 93: 1057-1062.
28. Kappler M, Taubert H, Bartel F, Blumke K, Panian M, Schmidt H et al. Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 2005; 13: 167-172.
29. Li F, Ling X. Survivin study: an update of 'what is the next wave'? J Cell Physiol 2006; 208: 476-486.
30. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-6102.
31. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005; 4: 11.
32. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 2004; 314: 902-907.
33. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005; 92: 212-216.
34. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 2002; 9: 1334-1342.
35. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005; 24: 1994-2007.
36. Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ko FP et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 2006; 281: 1286-1295.
37. Taubert H, Kappler M, Bache M, Bartel F, Kohler T, Lautenschlager C et al. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene 2005; 24: 5258-5261.
38. Yang L, Cao Z, Li F, Post DE, Van Meir EG, Zhong H et al. Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Therapy 2004; 11: 1215-1223.
39. Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001; 158: 1757-1765.
40. Bache M, Holzapfel D, Kappler M, Holzhausen HJ, Taubert H, Dunst J et al. Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy. Gynecol Oncol 2007; 104: 139-144.
41. Taubert H, Schmidt H, Würl P, Hinze R, Meye A, Bache M et al. Morphological and molecular characterization of an undifferentiated soft tissue sarcoma cell line and derivative clones. Int J Oncol 1997; 25: 521-526.
42. Kummermehr J, Malinen E, Freykowski S, Sund M, Trott KR. The influence of autologous tumor fibroblasts on the radiosensitivity of squamous cell carcinoma megacolonies. Int J Radiat Oncol Biol Phys 2001; 50: 229-237.
43. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001; 84: 1070-1075.
44. Shintani K, Matsumine A, Kusuzaki K, Matsubara T, Satonaka H, Wakabayashi T et al. Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch 2006; 449: 673-681.
45. Ueda Y, Nakagawa T, Kubota T, Ido K, Sato K. Glioma cells under hypoxic conditions block the brain microvascular endothelial cell death induced by serum starvation. J Neurochem 2005; 95: 99-110.
46. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006; 281: 25903-25914.
47. Chang Q, Qin R, Huang T, Gao J, Feng Y. Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas 2006; 32: 297-305.
48. Kwon DS, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells. Eur J Cell Biol 2006; 85: 1189-1199.
49. Li F. Survivin study: what is the next wave? J Cell Physiol 2003; 197: 8-29.